SmallCap Trading Techniques

[I Like Bottom Fishing]

GNBT News Generex Biotechnology Corporation to Hold Conferen...
Wednesday, June 18, 2008 3:28 PM

From:
"[e-mail]" <[e-mail]>
View contact details

Scottrade.com
This email is compliments of Scottrade.com

If you would like to modify or suspend this alert, please login to your Scottrade account and navigate to the "Alerts" page under the "My Account" tab.


News for 'GNBT' - (Generex Biotechnology Corporation to Hold Conference Call On Tuesday, June 24th to Update Investors On Phase III Trial of Generex Oral-lyn and Other Corporate Activities)


WORCESTER, Mass., Jun 18, 2008 (PrimeNewswire via COMTEX) -- Generex
Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in
drug delivery for metabolic diseases through the inner lining of the mouth,
announced today that it will hold a conference call on Tuesday, June 24, 2008 at
11 a.m. Eastern Time to update the investment community on its Phase III
clinical trial of the Company's flagship product, Generex Oral-lyn(tm), an oral
insulin spray, activity in the regions where the Company's products have been
approved for sale, and progress at its Antigen Express wholly-owned subsidiary.

"We are very excited by the recent progress we have made in the trial of Generex
Oral-lyn(tm) and look forward to updating investors on this and other corporate
activities," said Anna Gluskin, Generex Biotechnology's Chairman and CEO.

Interested parties should dial 888-656-7428 (domestically) or 913-312-1523
(internationally) and reference passcode 4975500. There will be a replay
available for five days following completion of the call. To listen to the
replay, parties should dial 888-203-1112 (domestically) or 719-457-0820
(internationally) and reference passcode 4975500. The call will also be webcast
on the Company's web site at www.generex.com on the Home Page of the Investor
Relations section.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist(tm)
device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)),
which is available for sale in Ecuador for the treatment of patients with Type-1
and Type-2 diabetes and which was approved for sale in India in October 2007, is
in Phase 3 clinical trials at several sites around the world. For more
information, visit the Generex website at http://www.generex.com.

The Generex Biotechnology Corp. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex
representatives concerning the same subject matter may contain "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements can be identified by introductory words such as
"expects," "plans," "intends," "believes," "will," "estimates," "forecasts,"
"projects" or words of similar meaning, and by the fact that they do not relate
strictly to historical or current facts. Forward-looking statements frequently
are used in discussing potential product applications, potential collaborations,
product development activities, clinical studies, regulatory submissions and
approvals, and similar operating matters. Many factors may cause actual results
to differ from forward-looking statements, including inaccurate assumptions and
a broad variety of risks and uncertainties, some of which are known and others
of which are not. Known risks and uncertainties include those identified from
time to time in the reports filed by Generex with the Securities and Exchange
Commission, which should be considered together with any forward-looking
statement. No forward-looking statement is a guarantee of future results or
events, and one should avoid placing undue reliance on such statements. Generex
undertakes no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. Generex
cannot be sure when or if it will be permitted by regulatory agencies to
undertake additional clinical trials or to commence any particular phase of
clinical trials. Because of this, statements regarding the expected timing of
clinical trials cannot be regarded as actual predictions of when Generex will
obtain regulatory approval for any ``phase'' of clinical trials. Generex claims
the protection of the safe harbor for forward-looking statements that is
contained in the Private Securities Litigation Reform Act.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Generex Biotechnology Corp.


By Staff

CONTACT: CEOcast, Inc. Gary Nash 212-732-4300 American Capital Ventures, Inc. Howard Gostfrand 305-918-7000




(C) Copyright 2008 PrimeNewswire, Inc. All rights reserved.

-0-




INDUSTRY KEYWORD: Biotechnology

SUBJECT CODE: BIOTECHNOLOGY

CONFERENCE

Calendar of Events

Health

Source: Comtex Wall Street News
Go to Previous message | Go to Next message | Back to Messages
ASCII (ASCII)Greek (ISO-8859-7)Greek (Windows-1253)Latin-10 (ISO-8859-16)Latin-3 (ISO-8859-3)Latin-6 (ISO-8859-10)Latin-7 (ISO-8859-13)Latin-8 (ISO-8859-14)Latin-9 (ISO-8859-15)W. European (850)W. European (CP858)W. European (HPROMAN8)W. European (MACROMAN8)W. European (Windows-1252)Armenia (ARMSCII-8)Baltic Rim (ISO-8859-4)Baltic Rim (WINDOWS-1257)Cyrillic (866)Cyrillic (ISO-8859-5)Cyrillic (KOI8-R)Cyrillic (KOI8-RU)Cyrillic (KOI8-T)Cyrillic (KOI8-U)Cyrillic (WINDOWS-1251)Latin-2 (852)Latin-2 (ISO-8859-2)Latin-2 (WINDOWS-1250)Turkish (ISO-8859-9)Turkish (WINDOWS-1254)Arabic (ISO-8859-6, ASMO-708)Arabic (WINDOWS-1256)Hebrew (856)Hebrew (862)Hebrew (WINDOWS-1255)Chinese Simplified (GB-2312-80)Chinese Simplified (GB18030)Chinese Simplified (HZ-GB-2312)Chinese Simplified (ISO-2022-CN)Chinese Simplified (WINDOWS-936)Chinese Trad.-Hong Kong (BIG5-HKSCS)Chinese Traditional (BIG5)Chinese Traditional (EUC-TW)Japanese (SHIFT_JIS)Japanese (EUC-JP)Japanese (ISO-2022-JP)Korean (ISO-2022-KR)Korean (EUC-KR)Thai (TIS-620-2533)Thai (WINDOWS-874)Vietnamese (TCVN-5712)Vietnamese (VISCII)Vietnamese (WINDOWS-1258)Unicode (UTF-7)Unicode (UTF-8)Unicode (UTF-16)Unicode (UTF-32)
| Full Headers
Search Mail